The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (NCT05938712)
A Two Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of the Combined Use of Once Daily 10mg Dapagliflozin and Once Weekly 1.0mg Semaglutide in Kidney Transplant Recipients
🩺 Plain-English Summary (8th-Grade Level)
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (19 items).
Location: Toronto General Hospital — Toronto, Ontario
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Type 1 diabetes.
- History of multi-organ transplant
- Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
- Impending need for kidney biopsy or rapid decline in eGFR within 30 days prior to screening
- Actively treated BK, CMV or EBV infection
- Recurrent pyelonephritis or need for indwelling or self-catheterization
- Prior amputation or ischemic rest pain
- Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.
- History of pancreatitis
- Personal or family history or medullary thyroid cancer or MEN2B
- History of unstable diabetic retinopathy within 1 year prior to screening
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Toronto General Hospital — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 340-4800
Email: vesta.lai@uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant Recipients
- Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients — Boston, Massachusetts
- Velocity-Based Resistance Training in Kidney Transplant Recipients — Bogotá, Bogota D.C.
Explore by condition: All Kidney Transplant Recipients clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.